Arrien Pharmaceuticals is a small molecule targeted therapeutics drug discovery and development company working towards targeting kinase signaling and nuclear receptor pathways - A target class in treating Inflammation, Autoimmune, Cancer, and Neurodegenerative diseases. The Arrien Pharmaceuticals successfully applied and applying its proprietary platform FIELDS technology and discovered a pipeline of uniquely positioned pre-clinical stage programs for future treatment of Multiples Sclerosis (MS), Psoriasis, Cancer (Ovarian, Breast, Prostate, DLBCL, and Lung), Rheumatoid Arthritis (RA), and Parkinson's Diseases.

Arrien Pharmaceuticals FIELDS technology is a Fragment-Based Drug Design typically involves empirical and structural data input assisting our Medicinal Chemists in early phase of lead-to-drug-lead design process. Arrien Pharmaceuticals cost-competent approach rapidly aid our scientific team in selecting pre-clinical candidate ready compounds.

Arrien Pharmaceuticals advanced ARN-6039, ARN-3261 and ARN-4079 programs into IND enabling studies.

Arrien Pharmaceuticals competitive and unique drug discovery approaches coupled with experienced scientific and management team with expertise in multidisciplinary areas of medicinal, biological and Clinical Sciences has been the key to company's technology and success since its incorporation in 2011.